NCT06390956

Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)

A Phase II Study of Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 23 (estimated)
• Sponsor: University of Utah · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this clinical trial is to learn if the drugs Pirtobrutinib and Rituximab are effective for the treatment of newly diagnosed marginal zone lymphoma.

Conditions

• Marginal Zone Lymphoma

Interventions

Type	Name	Description
DRUG	Pirtobrutinib	Administered once daily as an oral medication.
DRUG	Rituximab	Rituximab is a sterile, clear, colorless, preservative-free liquid concentrate for intravenous (IV) administration. The product is formulated for intravenous administration in 9.0 mg/mL sodium chloride, 7.35 mg/mL sodium citrate dihydrate, 0.7 mg/mL polysorbate 80, and Sterile Water for Injection.

Timeline

• Start date: 2025-02-20
• Primary completion: 2031-12-01
• Completion: 2032-12-01
• First posted: 2024-04-30
• Last updated: 2025-12-04

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study